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Objectives: Venous thromboembolism (VTE) is a common complication for can-
cer patients, leading to hospitalizations that increase the cost of management of 
these patients. The objective of the present study was to evaluate the number and 
the cost of VTE-related hospitalizations for patients with breast or prostate cancer 
during the two first years of their oncologic treatment. MethOds: Patients with 
breast cancer (BC) or prostate cancer (PC) diagnosed in 2010 who had at least one 
VTE-related hospitalization during the following two years were selected from the 
French national hospital database (PMSI), using the disease-specific ICD-10 codes. 
Hospital costs were estimated from the third-party payer perspective using the 
official diagnosis related group (DRG) tariffs for each year considered. Results: In 
2010,62,365 patients newly diagnosed with BC and 45,551 with PC were admitted 
in French hospitals. Among them, 1,271 in the BC cohort (2.0%) and 997 in the PC 
cohort (2.2%) were hospitalized for VTE at least once during the two-year follow-
up, leading to 1,604 stays for BC patients and 1,210 stays for PC patients. During a 
2-years follow-up, 15.9% of BC patients and 14.4% of PC patients were re-hospitalized 
for VTE recurrence. The mean cost per stay was 3,261€ and 3,584€ for BC and PC 
respectively. Mean cost per patient was estimated at 3,302€ and 3,611€ for BC and 
PC patients hospitalized once for VTE-related events, and it increased to 5,545€ and 
5,692€ for BC and PC patients who presented recurrences. Over a 2-year period, total 
hospital cost induced by VTE-related events reached 1.98 million and 1.43 million € 
for BC and PC, respectively. cOnclusiOns: VTE-related hospitalizations in breast 
or prostate cancer patients lead to a significant economic burden that could be 
reduced by decreasing VTE recurrence.
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Objectives: To examine the economic burden and health care utilization of 
melanoma patients in the U. S. Medicare population. MethOds: A retrospec-
tive database analysis was performed using U. S. national Medicare claims from 
01JAN2008 to 31DEC2012. Melanoma patients were identified using International 
Classification of Disease 9thRevision Clinical Modification (ICD-9-CM) diagnosis 
code 172. xx. The first diagnosis date was designated as the index date. A compara-
tor group was created, consisting of patients with the same age, region, gender, 
index year, and matched baseline Charlson Comorbidity Index scores but with-
out a melanoma diagnosis. A random index date was chosen for the comparator 
cohort to reduce selection bias. Patients were required to have continuous medical 
and pharmacy benefits 1 year pre- and post-index date. One-to-one propensity 
score matching (PSM) was performed to compare follow-up health care costs and 
utilizations between the cohorts, adjusting for demographic and clinical charac-
teristics. Results: Eligible patients (N= 12,762) were identified for the melanoma 
and comparison cohorts. After 1: 1 PSM, a total of 8,015 patients were matched 
from each cohort and baseline characteristics were well-balanced. More melanoma 
patients had health care utilizations, including Medicare carrier (99.6% vs. 64.3%), 
Durable Medical Equipment (DME; 19.8% vs. 14.4%) and Home Health Agency 
(HHA; 6.7% vs. 4.1%) claims, outpatient visits (68.4% vs. 35.4%), inpatient (10.9% 
vs. 6.6%) and skilled nursing facility (SNF) stays (2.4% vs. 1.7%), but fewer mela-
noma patients had prescription clams (43.6% vs. 49.8%). Patients diagnosed with 
melanoma incurred higher expenditures, including carrier ($3,527 vs. $1,324), DME 
($153 vs. $101), HHA ($325 vs. $203), outpatient ($8,816 vs. $3,151), inpatient ($1,725 
vs. $1,154) and total health care costs ($15,692 vs. $6,990) (p< 0.0001). Similar SNF, 
hospice and pharmacy claim costs were observed in both cohorts. cOnclusiOns: 
Patients diagnosed with melanoma had a higher burden of illness compared to 
the comparison cohort of non-melanoma patients.
PCN68
resourCe use ANd heAlth CAre Costs of CerviCAl lesioNs ANd 
CerviCAl CANCer iN slovAkiA
Ondrusova M.1, Psenkova M.1, Mlyncek M.2, Masak L.3, Hlavinkova L.4, Trnovec P.4
1Pharm-In Ltd, Bratislava, Slovak Republic, 2Faculty Hospital and Constantine the Philosopher 
University, Nitra, Slovak Republic, 3Cancer Institute St. Elizabeth, Bratislava, Slovak Republic, 
4GlaxoSmithKline Slovakia, Bratislava, Slovak Republic
Objectives: The objective of this cost study was to measure the resource utilisa-
tion and direct costs associated with health care management of cervical abnormal 
cytology and cervical cancer in Slovakia and to provide a basis for cost-effective-
ness evaluations. MethOds: The cross-sectional survey was performed to obtain 
the information on the management of patients with cervical lesions (Low Grade 
Squamous Intraepithelial Lesion (LSIL), High Grade Squamous Intraepithelial Lesion 
(HSIL), Atypical Squamous Cells of Undetermined Significance (ASCUS), Cervical 
Intraepithelial Neoplasia (CIN) I-III) and cervical cancer (clinical stages IA1 to IVB) 
and to estimate the direct costs of the disease management. All types of health care 
used in the management of cervical lesions/cancer were evaluated (diagnostics, 
treatment and follow-up). Average costs per patient were assessed on a yearly basis 
and correspond to the prices in 2013. Results: Concerning the cervical lesions, the 
highest mean annual costs were identified in the CIN III (36.45%; € 1406.62), followed 
by CIN II (27.0%; € 1041.97), the most costly part of health care management being 
the treatment of lesions. The costs of health care management of cervical cancer 
depended on the clinical stage and the frequency of examinations during the year. 
The highest total costs (follow-up included) were identified in the stage III (19.33%; 
€ 4633.35) and IVB (14.24%; € 3413.22). However, the highest mean annual costs of 
diagnostics were determined in stage IB (15.39%; € 542.12), IIA (15.46%; € 544.33), 
IVA and IVB (14.89%; € 524.33). The most expensive treatment (including surgery, 
radiotherapy, concomitant chemoradiotherapy and palliative chemotherapy) was 
identified in the stage IIB (20.89%; € 3616.38) and III (21.01%; € 3637.79). In the most 
advanced stages IVA and IVB, the treatment expenses were lower. Follow-up man-
agement was the most expensive in the stage IVB (15%; € 531.66). cOnclusiOns: 
that their findings can neither be extrapolated to the general patient population 
nor to other points along the pathway. Based on empirical data from a representa-
tive population-based patient cohort, the objective of this study was to develop 
a simulation model that could predict costs at an individual level and estimate 
the real medical costs of treating DLBCL. MethOds: All patients newly diagnosed 
with DLBCL in the UK’s population-based Haematological Malignancy Research 
Network (www.hmrn.org) in 2007 were followed until 2013 (n= 271). The mapped 
treatment pathways, alongside cost information derived from the National Tariff 
2013/14, were incorporated into a patient level simulation model in order to reflect 
the heterogeneities of patient characteristics and treatment options. Results: 
The expected total medical costs were £23,184 for those treated curatively with 
chemotherapy and £2,125 for those with a palliative approach over a period of five 
years. The predicted medical cost of the first line was £15,243, and £16,325 and 
£7,145 for the second line and the third line treatments respectively. The predicted 
costs captured 94% of the actual costs and the proportion of patients simulated in 
each health state was identical to the empirical data, supporting the validity of the 
model. cOnclusiOns: This is the first cost modelling study to use empirical data 
to provide ‘real world’ evidence to estimate medical costs of entire DLBCL treatment 
pathways. Future application of the model developed here could be used to evaluate 
new technologies/treatments and support health care decision makers, especially 
in the era of personalised medicine.
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Objectives: Prevention of chemotherapy-induced nausea and vomiting (CINV) 
remains an important goal for patients receiving cytotoxic treatment. The objec-
tive of this study was to assess, from the Italian National Health Service payer 
perspective, the costs of an antiemetic regimen using aprepitant, a selective neu-
rokinin-1 receptor antagonist, for patients receiving highly emetogenic chemo-
therapy. MethOds: A decision-analytic model was developed to compare an 
aprepitant regimen (aprepitant, ondansetron, and dexamethasone) with a standard 
antiemetic regimen (ondansetron and dexamethasone) for expected costs after 
highly emetogenic chemotherapy. The model was populated with clinical results 
from patients with high-dose cisplatin treatment in a randomized trial of CINV 
preventative therapy. Only direct medical costs (pharmacological treatment and 
emesis) – Euro 2014 – were considered. Sensitivity and Threshold analyses on key 
clinical and economic parameters were performed. Results: Aprepitant regimen 
showed the lower expected treatment cost (aprepitant regimen: € 109.88; standard 
antiemetic regimen € 115.57). The drug acquisition cost of the aprepitant regimen 
(aprepitant regimen: € 86.16; standard antiemetic regimen € 79.37) was offset by 
reduced health care resource utilization costs for CINV (aprepitant regimen: € 23.72; 
standard antiemetic regimen: € 36.20). Sensitivity and Threshold analysis confirmed 
the base case results. cOnclusiOns: The results of this cost-consequence analysis 
suggest that, from the Italian National Health Service payer perspective, aprepi-
tant regimen is a cost-saving strategy compared with antiemetic regimen without 
aprepitant in the prevention of highly emetogenic chemotherapy-induced nausea 
and vomiting.
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Objectives: Evaluate and compare the cost of non-small cell lung cancer (NSCLC) 
treatment by different standards of treatment in Vietnam. MethOds: A tree-deci-
sion model has been developed to estimate the cost of NSCLC. The analysis has 
been conducted based on the perspective of health insurance companies, there-
fore only medical direct costs, including cost for drugs and medical services has 
been evaluated. The list of medical services and drugs was derived from NCCN 
Clinical Practice Guidelines in Oncology (NCCN therapy) and Lung Cancer Therapy 
of Vietnam National Cancer Hospital (Vietnam therapy). The transition rates in the 
model were derived from clinical researches and consultation with experts. The 
cost of drugs and medical services has been averaged from the relevant medical 
services of some major hospitals in Vietnam. Results: The total treatment costs 
increase following the severity of stage whether treatment was implemented by 
Vietnamese or European standards. Moreover, in all stages of disease, the total 
treatment costs of NSCLC by Vietnamese guideline are less than that by NCCN 
standard (74,425,114 vs 79,729,000 in phase I; 139,031,940 vs 210,585,139 in phase II, 
172,333,617 vs 339,542,672 VND in phase III, and 160,690,121 VND vs 266,197,825 VND 
in phase IV, respectively). This can be explained by the lack of some expensive drugs 
and medical services in Vietnam due to the socio-economic conditions of Vietnam. 
In the structure of costs, cost for drugs take the dominant part with approximately 
76.61% by NCCN standard and 74.92% by Vietnamese standard, which is almost 3 
times higher than that of medical services. cOnclusiOns: The high cost of NCSLC 
should be considered to conduct the relevant health care policies, especially with 
high-cost drugs in late stages of disease. The cost of NSCLC treatment by NCCN 
therapy is higher than the cost of NSCLC treatment by Vietnam therapy.
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